Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Claus-Henning Kohne"'
Autor:
Christine Stürken, Volker Möbus, Karin Milde-Langosch, Sabine Schmatloch, Peter A. Fasching, Josef Rüschoff, Elmar Stickeler, Rolf-Peter Henke, Carsten Denkert, Lars Hanker, Christian Schem, Valentina Vladimirova, Thomas Karn, Valentina Nekljudova, Claus-Henning Köhne, Frederik Marmé, Udo Schumacher, Sibylle Loibl, Volkmar Müller
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Breast cancer (BC) is the most frequent female cancer and preferentially metastasizes to bone. The transcription factor TGFB-induced factor homeobox 1 (TGIF) is involved in bone metabolism. However, it is not yet known whether TGI
Externí odkaz:
https://doaj.org/article/c69ff00bda2f4529a85614e57c4f1988
Autor:
Gerald Prager, Claus-Henning Köhne, Juan Manuel O’Connor, Fernando Rivera, Daniele Santini, Harpreet Wasan, Jean Marc Phelip
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 2097-2106 (2021)
The SCOPE project aimed to better understand practice patterns, identify drivers for treatment goals, and determine third- and fourth-line treatment choices for patients with metastatic colorectal cancer (mCRC). The survey was developed by an expert
Externí odkaz:
https://doaj.org/article/e319e34fd9e347e0b2634a2c20338756
Autor:
Claus-Henning Köhne, Meinolf Karthaus, Laurent Mineur, Josef Thaler, Marc Van den Eynde, Javier Gallego, Reija Koukakis, Marloes Berkhout, Ralf-Dieter Hofheinz
Publikováno v:
Drugs in R&D, Vol 19, Iss 3, Pp 267-275 (2019)
Abstract Objective Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer were retrospectively analysed to investigate the effects of primary tumour location a
Externí odkaz:
https://doaj.org/article/e5ea3fd307224aeab0e585693366cc17
Autor:
Christine Stürken, Volker Möbus, Karin Milde-Langosch, Sabine Schmatloch, Peter A. Fasching, Josef Rüschoff, Elmar Stickeler, Rolf-Peter Henke, Carsten Denkert, Lars Hanker, Christian Schem, Valentina Vladimirova, Thomas Karn, Valentina Nekljudova, Claus-Henning Köhne, Frederik Marmé, Udo Schumacher, Sibylle Loibl, Volkmar Müller
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/c9d26cf8ebe64f5d8bb80d323fe092e0
Autor:
Christian Michel, Andreas Burchert, Andreas Hochhaus, Susanne Saussele, Andreas Neubauer, Michael Lauseker, Stefan W. Krause, Hans-Jochem Kolb, Dieter Kurt Hossfeld, Christoph Nerl, Gabriela M. Baerlocher, Dominik Heim, Tim H Brümmendorf, Alice Fabarius, Claudia Haferlach, Brigitte Schlegelberger, Leopold Balleisen, Maria-Elisabeth Goebeler, Mathias Hänel, Anthony Ho, Jolanta Dengler, Christiane Falge, Robert Möhle, Stephan Kremers, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, Hans-Walter Lindemann, Cornelius F. Waller, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiri Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, Winfried Gassmann, Michael Schenk, Peter Brossart, Thomas Wündisch, Thomas Geer, Stephan Bildat, Erhardt Schäfer, Joerg Hasford, Rüdiger Hehlmann, Markus Pfirrmann
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition with 800 mg (‘high-dose’) imatinib accelerated achievement of a deep mo
Externí odkaz:
https://doaj.org/article/8f2e3c990dda4c23bf1aba8a1a3b48ba
Publikováno v:
Therapeutic Advances in Urology, Vol 9 (2017)
Vinflunine (VFL) has been approved in Europe for second-line treatment of metastatic and advanced urothelial cancer after failure of platin-containing therapy. Since approval, the drug has been investigated in few clinical trials. Most of the current
Externí odkaz:
https://doaj.org/article/0a4c8420741b430ab844895899044c29
Autor:
Enriqueta Felip, Josep Tabernero, Maria De Santis, Emile Voest, Mark Robson, Fatima Cardoso, Elisabeth G E de Vries, Fedro Alessandro Peccatori, Svetlana Jezdic, Giannis Mountzios, Smita Bhatia, Alexandru Eniu, Luzia Travado, Ulrich Keilholz, Jonas Bergh, Jan Buckner, Friedrich Stiefel, Ahmad Awada, Cristiana Sessa, Olivier Michielin, Marc Ernstoff, Ben Markman, Lisa Licitra, Rossana Berardi, Jill Gilbert, Lidia Schapira, Eva Schernhammer, Jeffrey S Weber, Heinz-Josef Lenz, Piotr Rutkowski, Jennifer Duff, Axel Grothey, Yuichiro Ohe, Saskia Litiere, Hans Wildiers, Christian Dittrich, Michael Kosty, Doug Pyle, Nagi El-Saghir, Jean-Pierre Lotz, Pia Österlund, Nicholas Pavlidis, Gunta Purkalne, Susana Banerjee, Jan Bogaerts, Paolo Casali, Edward Chu, Julia Lee Close, Bertrand Coiffier, Roisin Connolly, Sarah Coupland, Luigi De Petris, Don S Dizon, Linda R Duska, Martin F Fey, Nicolas Girard, Andor W J M Glaudemans, Priya K Gopalan, Stephen M Hahn, Diana Hanna, Christian Herold, Jørn Herrstedt, Krisztian Homicsko, Dennie V Jones, Lorenz Jost, Saad Khan, Alexander Kiss, Claus-Henning Köhne, Rainer Kunstfeld, Stuart Lichtman, Thomas Lion, Lifang Liu, Patrick J Loehrer, Merry Jennifer Markham, Marius Mayerhoefer, Johannes G Meran, Elizabeth Charlotte Moser, Timothy Moynihan, Torsten Nielsen, Kjell Öberg, Antonio Palumbo, Michael Pfeilstöcker, Chandrajit Raut, Scot C Remick, Roberto Salgado, Martin Schlumberger, Hans-Joachim Schmoll, Lowell Schnipper, Charles L Shapiro, Julie Steele, Cora N Sternberg, Florian Strasser, Roger Stupp, Richard Sullivan, Marcel Verheij, Everett Vokes, Jamie Von Roenn, Yosef Yarden
Publikováno v:
ESMO Open, Vol 1, Iss 5 (2016)
The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) thanks to contribution of 64 ESMO-appointed and 32 ASCO-appointed authors. Firs
Externí odkaz:
https://doaj.org/article/03442ec458e245ef83ebe8453a3f265c
Autor:
Marie-Luise Hütter-Krönke, Axel Benner, Konstanze Döhner, Jürgen Krauter, Daniela Weber, Margit Moessner, Claus-Henning Köhne, Heinz A. Horst, Ingo G.H. Schmidt-Wolf, Mathias Rummel, Katharina Götze, Elisabeth Koller, Andreas L. Petzer, Hans Salwender, Walter Fiedler, Heinz Kirchen, Detlef Haase, Stephan Kremers, Matthias Theobald, Axel C. Matzdorff, Arnold Ganser, Hartmut Döhner, Richard F. Schlenk
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m2 intravenously on day 1), all-trans retinoic acid (45 mg/m2 orally on day
Externí odkaz:
https://doaj.org/article/e94817aacaec41859b402566beb720a7
Autor:
Peter Paschka, Richard F. Schlenk, Verena I. Gaidzik, Julia K. Herzig, Teresa Aulitzky, Lars Bullinger, Daniela Späth, Veronika Teleanu, Andrea Kündgen, Claus-Henning Köhne, Peter Brossart, Gerhard Held, Heinz-A. Horst, Mark Ringhoffer, Katharina Götze, David Nachbaur, Thomas Kindler, Michael Heuser, Felicitas Thol, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Publikováno v:
Haematologica, Vol 100, Iss 3 (2015)
We studied 1696 patients (18 to 61 years) with acute myeloid leukemia for ASXL1 mutations and identified these mutations in 103 (6.1%) patients. ASXL1 mutations were associated with older age (P
Externí odkaz:
https://doaj.org/article/b41d795d0b9c479199150506c6c6f94a